BSE: 543654 MEDANTA NSE

GLOBAL HEALTH LIMITED (543654) — Latest Corporate Announcements

₹1,280 ₹-29.40 (-2.25%)

Market Cap ₹34,396.39 Cr

P/E Ratio 61.75

52W Range ₹956 – ₹1544

Corporate Actions & Regulatory Filings

Financial Results (Quarterly & Annual)

Quarter / Period	Meeting / Outcome Date	Status	Filing Details
Quarter Ended 30-Jun-2026 (Q1 FY27)	30-Jul-2026	Declared	To consider and approve the financial results for the period ended Jun 30, 2026
Year Ended 31-Mar-2026 (Q4 FY26)	14-May-2026	Declared	To consider and approve the financial results for the quarter and year ended March 31, 2026 and recommendation of final dividend, if any subject to shareholders approval.
Quarter Ended 31-Dec-2025 (Q3 FY26)	04-Feb-2026	Declared	To consider and approve the financial results for the Third Quarter and Nine Months ended December 31, 2025.
Quarter Ended 30-Sep-2025 (Q2 FY26)	07-Nov-2025	Declared	To consider and approve the un-audited financial results for the period ended September 30, 2025
Quarter Ended 30-Jun-2025 (Q1 FY26)	07-Aug-2025	Declared	To consider and approve the financial results for the period ended Jun 30, 2025
Year Ended 31-Mar-2025 (Q4 FY25)	15-May-2025	Declared	To consider and approve the financial results for the quarter and year ended March 31, 2025 and recommend the final dividend, if any subject to shareholders approval.
Quarter Ended 31-Dec-2024 (Q3 FY25)	04-Feb-2025	Declared	To consider and approve the financial results for the period ended December 31, 2024
Quarter Ended 30-Sep-2024 (Q2 FY25)	14-Nov-2024	Declared	To consider and approve the financial results for the period ended September 30, 2024
Quarter Ended 30-Jun-2024 (Q1 FY25)	08-Aug-2024	Declared	To consider and approve the financial results for the period ended Jun 30, 2024
Year Ended 31-Mar-2024 (Q4 FY24) (STD & CONSOL)	17-May-2024	Declared	To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the Fourth Quarter and Financial Year ended March 31, 2024.
Quarter Ended 31-Dec-2023 (Q3 FY24)	08-Feb-2024	Declared	To consider and approve the financial results for the period ended December 31, 2023
Quarter Ended 30-Sep-2023 (Q2 FY24)	09-Nov-2023	Declared	To consider and approve the financial results for the period ended September 30, 2023

Track Related Peer Equities

RELIANCE Track Reliance Industries Ltd Filings → TCS Track Tata Consultancy Services Ltd Filings → HDFCBANK Track HDFC Bank Ltd Filings → INFY Track Infosys Ltd Filings →

Related Research Guides & Regulatory Playbooks

SEBI LODR Regulation 30 Material Disclosures, Timelines & Filing Rules → Results Calendar Guide Earnings Dates, Board Notices & LODR Reg 33 → Shareholding Patterns Promoter Staking, Pledging & FII/DII Reg 31 → Insider Trading & PIT Trading Window Closures & Promoter Filings →

Frequently Asked Questions about GLOBAL HEALTH LIMITED BSE Disclosures

What is the latest BSE announcement by GLOBAL HEALTH LIMITED?

The latest BSE disclosure by GLOBAL HEALTH LIMITED (MEDANTA), filed on 2026-10-12T13:17:41, is: "Global Health Ltd - 543654 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018". Bsenexus tracks every official filing for GLOBAL HEALTH LIMITED with AI-powered summaries on its announcements feed.

When is GLOBAL HEALTH LIMITED's next board meeting?

No upcoming board meeting is currently tracked for GLOBAL HEALTH LIMITED. Companies disclose meeting intimations under SEBI LODR, and scheduled dates appear on the Bsenexus Results Calendar.

When does GLOBAL HEALTH LIMITED declare quarterly results?

Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. GLOBAL HEALTH LIMITED's recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.

Track GLOBAL HEALTH LIMITED Announcements on Bsenexus Live Terminal →